ELI LILLY

More in ELI LILLY

• Lilly files additional lawsuits over US sales of counterfeit Mounjaro

  In an open letter, Lilly warned that unsafe or untested compounded tirzepatide puts patients at risk and that it stands against the use of its treatments for cosmetic weight loss.

  

• Eli Lilly exec expects obesity pill data in April 2025

  ​Drugs from the class are also being tested to treat Alzheimer's. Patrik Jonsson, President of Lilly Diabetes and Obesity, speaking at a Goldman Sachs healthcare conference, said his company is not convinced that the drug will help with the disease itself, but might help with underlying conditions like obesity and stroke that lead to cognitive decline.

  

• US FDA staff raise no major concerns about Eli Lilly Alzheimer's drug

  An outside panel of FDA advisers will consider the staff's view during a meeting on Monday in which they will vote on whether the drug's benefits outweigh its risks, according to documents published on the agency's website.

  

• Structure's obesity drug reduces more weight than expected in study

  Leerink analysts said in a note before the data that they expected weight loss of between 5 per cent to 6 per cent in the trial at the end of 12 weeks, compared with 6 per cent to 7 per cent from Lilly's trial of its oral weight loss drug orforglipron

  

• Weight-loss drug forecasts jump to $150 billion as supply grows

  Global spending on obesity medications totaled $24 billion last year, IQVIA estimated in its latest five-year outlook, and could reach $131 billion by 2028. That 27 per cent annual growth estimate compares with a prior projection of 13 per cent.

  

• Aktis to collaborate with Eli Lilly on cancer therapies

  The Boston-based drug developer will use its proprietary technology along with Lilly's expertise in oncology drugs to develop therapies for a range of solid tumors.

  

• Eli Lilly's diabetes drug tirzepatide gets approval in China

  Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by decade's end. Both companies' obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.

  

• Swiss pharma supplier Lonza flags signs of recovery in biotech funding

  ​Lonza's business was weighed down last year by drug developers pursuing fewer early stage ventures. Outgoing CEO Albert Baehny, who will be replaced by Wolfgang Wienand this summer, said the company had already seen signs of improvement, but would likely see a clear rebound only in 2025.

  

• Denmark faces Wegovy shortage due to rising demand

  There will be a shortage of Novo Nordisk's Wegovy Flextouch 1 milligram pen from late May to mid-June, the Danish medicines agency said in a statement.

  

• Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows

  ​Still, affordability remains a challenge. Adults with annual household incomes of $90,000 or greater were more likely than those with lower household incomes to say they have heard "a lot" about these drugs, the poll showed.

  

• US FDA panel to discuss Eli Lilly Alzheimer's drug on June 10

  Donanemab has faced two separate regulatory delays in the United States, while a similar therapy by Eisai and partner Biogen, called Leqembi, received the U.S. Food and Drug Administration's approval last year.